Boston Scientific 8-K
RestructuringGuidance
Global restructuring targets supply-chain efficiencies and job cuts through 2029, with substantial savings expected to be reinvested in growth.
Filed 2026-07-27 16:06 ET
Alerts
Filing event
Restructuring
This filing includes Item 2.05. Exit or disposal costs are often part of a planned cost reduction; see the filing for the scope and costs.
An alert from the filing's SEC item codes, not from reading its text. Filing on SEC.gov
- 2.05 Costs of Exit or Disposal Activities
Summary
Boston Scientific approved a global restructuring plan on 7/21/2026. The plan includes supply-chain optimization, targeted functional changes and organizational restructuring to support cost efficiencies and growth; activities are expected to begin in 2026 and be substantially complete by the end of 2029. The company expects some headcount reductions alongside hiring in growth areas.
Key Figures
- Estimated total pre-tax charges: ≈$700M–$800M, including ≈$600M–$700M in future cash outlays. Estimated charges comprise $300M–$350M in transfer costs, $275M–$300M in termination benefits, and $125M–$150M in other costs.
- Expected gross annual pre-tax expense reductions: ≈$500M as benefits are realized; a substantial portion of savings is expected to be reinvested in strategic growth initiatives.
Investor Takeaways
- Watch implementation through the end of 2029 and whether the plan delivers the expected expense reductions as savings are realized.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3